Voyager Therapeutics (NASDAQ:VYGR) COO Robin Swartz Sells 6,458 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,458 shares of the business’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $3.77, for a total transaction of $24,346.66. Following the completion of the sale, the chief operating officer owned 199,738 shares of the company’s stock, valued at $753,012.26. The trade was a 3.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Robin Swartz also recently made the following trade(s):

• On Tuesday, February 10th, Robin Swartz sold 4,569 shares of Voyager Therapeutics stock. The shares were sold at an average price of $3.85, for a total transaction of $17,590.65.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR traded up $0.04 during trading hours on Thursday, hitting $4.13. 151,278 shares of the company’s stock were exchanged, compared to its average volume of 584,842. The company’s 50-day moving average price is $3.86 and its 200-day moving average price is $4.11. Voyager Therapeutics, Inc. has a 1-year low of $2.64 and a 1-year high of $5.55. The stock has a market capitalization of $229.63 million, a price-to-earnings ratio of -1.91 and a beta of 1.30.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on VYGR shares. HC Wainwright cut their target price on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Wall Street Zen lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Finally, Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.75.

Institutional Trading of Voyager Therapeutics

Several large investors have recently made changes to their positions in the business. Bank of Montreal Can bought a new stake in Voyager Therapeutics during the 2nd quarter worth about $36,000. Wexford Capital LP bought a new position in shares of Voyager Therapeutics in the third quarter worth about $42,000. ProShare Advisors LLC acquired a new position in shares of Voyager Therapeutics during the fourth quarter worth approximately $44,000. CIBC Asset Management Inc bought a new stake in shares of Voyager Therapeutics during the fourth quarter valued at approximately $45,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at approximately $50,000. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.